AI Article Synopsis
- Juvenile dermatomyositis (JDM) is a common inflammatory muscle disease in children that still causes significant health issues despite improvements in treatment.
- Different clinical types of JDM are linked to specific myositis-related antibodies, suggesting a correlation between the disease's manifestations and underlying biology.
- The paper discusses how combining clinical observations with molecular analysis can inform more effective targeted therapies by understanding the role of immune pathways in JDM.
Article Abstract
Juvenile dermatomyositis (JDM), the most common pediatric inflammatory myopathy, is associated with significant morbidity despite therapeutic advances. Distinct clinical phenotypes have emerged, which can correlate with myositis-specific antibodies. Because translational data solidify the role of type I IFNs in JDM disease pathogenesis, integration of clinical and molecular phenotyping may impact the choice of targeted therapy. This paper reviews clinical and molecular phenotyping in JDM and translational insights into immune pathogenesis that have created emerging options for targeted therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jid.2024.09.017 | DOI Listing |
Publication Analysis
Top Keywords
juvenile dermatomyositis
8
clinical phenotypes
8
clinical molecular
8
molecular phenotyping
8
targeted therapy
8
advances juvenile
4
dermatomyositis moving
4
moving integration
4
integration myositis-specific
4
myositis-specific antibody
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!